Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
一线化疗后接受度伐利尤单抗维持治疗HER2阴性晚期食管胃腺癌患者的疗效:来自随机PLATFORM研究的结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103622
Fong, C; Patel, B; Peckitt, C; Bourmpaki, E; Satchwell, L; Cromarty, S; Kidd, S; von Loga, K; Uhlik, M; Begum, R; Rana, T; Waddell, T; Darby, S; Bradshaw, A; Roques, T; Morgan, C; Rees, C; Herbertson, R; Das, P; Thompson, C; Hewish, M; Petty, R; Thistlethwaite, F; Rao, S; Starling, N; Chau, I; Cunningham, D